Literature DB >> 29858444

Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).

Indrajit Chattopadhyay1, Vedamurthy Adhiyaman1, Suhani Ghiya1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29858444      PMCID： PMC6334076          DOI： 10.7861/clinmedicine.18-3-267

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  4 in total

1.  Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine.

Authors:  Thomas Burden; Charlotte Thompson; Efstathios Bonanos; Andrew Rl Medford
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

2.  Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

Authors:  Vijay V Upreti; Jessie Wang; Yu Chen Barrett; Wonkyung Byon; Rebecca A Boyd; Janice Pursley; Frank P LaCreta; Charles E Frost
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 3.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Authors:  K Martin; J Beyer-Westendorf; B L Davidson; M V Huisman; P M Sandset; S Moll
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

Review 4.  A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?

Authors:  Ekrem Güler; Gamze Babur Güler; Gültekin Günhan Demir; Suzan Hatipoğlu
Journal:  Anatol J Cardiol       Date:  2015       Impact factor: 1.596
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.